Conflict of interest The author is an advisor to several regulatory agencies and governments
Weight Changes: Some may notice minimal weight loss or no significant changes during these first weeks as the body acclimates
Patients considering medically supervised weight loss should be aware of these restrictions: Section 503A pharmacies: Enforcement began April 22, 2025 Section 503B facilities: Must cease by May 22, 2025 Continued compounding may result in FDA enforcement actions Limited exceptions exist for documented allergies or specific medical needs Important Safety Note: The FDA strongly advises against using compounded semaglutide when FDA-approved alternatives are available
The honest answer is: partially
If youve done your research, you might be aware that Invokana is, sometimes, associated with a history of lower-limb amputation warnings
From the non-GLP RA group, 2,332,778 were excluded, resulting in 9,103,212 patients